Cozadd Bruce C sold 10,688 shares of Jazz Pharmaceuticals plc at $235.82 for −$2.52M on Nov 6, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Director
DIR
Filed Nov 10, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$2,520,465.54Shares × reported price
Shares traded
10,688Ordinary Shares
Price per share
$235.82Reported price. Read footnotes for ranges.
% of reported position traded
2.68%This security and ownership context
Holdings after
387,973Direct
Trade date
Nov 6, 2026Sell
Filed
Nov 10, 2026, 4:46 PM ET4-day reporting delay
Accession
0001193210-26-000032Code S · Transaction 397232
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 398,661 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 6, 2026Option exercise85,766$0.00$0Trade 397236
Nov 6, 2026Sell27,714$234.91−$6,510,356.71Trade 397231
Nov 6, 2026Sell24,483$236.84−$5,798,651.65Trade 397233
Nov 6, 2026Sell5,923$237.39−$1,406,042.61Trade 397234
Nov 6, 2026Option exercise734$136.18$99,956.12Trade 397229
Nov 6, 2026Option exercise85,766$136.18$11,679,613.88Trade 397230
Nov 6, 2026Option exercise734$0.00$0Trade 397235
8 transaction rows in this filing. Joint filers share the same rows.

JAZZ price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
JAZZ · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 17, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −5.8%1w ago −12%1d ago −7.4%
Returns since7d30d90d180d1y

Footnotes in full

F1: The sales of ordinary shares reported on this Form 4 were effected pursuant to a broker-assisted sell-to-cover exercise of fully vested stock options scheduled to expire on March 1, 2027. The ordinary shares were sold solely to cover the aggregate exercise price and applicable tax withholding obligations. The Reporting Person retained all remaining ordinary shares acquired upon exercise. F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $234.2650 to $235.2350. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $235.2700 to $236.2400. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $236.2900 to $237.2600. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F5: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $237.2900 to $237.7600. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F6: Exercise of stock options before their expiration date. F7: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 2, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.